Bailey.Glen at 21:36, 4 December 2023

2023-12-04T21:36:26Z

← Older revision		Revision as of 16:36, 4 December 2023
Line 16:		Line 16:
	==Cancer Category/Type==		==Cancer Category/Type==

	* [[Mature B-Cell Neoplasms]]		* [[HAEM4:Mature B-Cell Neoplasms]]

	==Cancer Sub-Classification / Subtype==		==Cancer Sub-Classification / Subtype==

	* [[Mantle ~~Cell Lymphoma~~]]		* [[HAEM5:Mantle cell lymphoma]]

	==Definition / Description of Disease==		==Definition / Description of Disease==
Line 59:		Line 59:
	***Leukemic involvement is usually a the sign of disease progression		***Leukemic involvement is usually a the sign of disease progression
	**Blastoid morphology of the circulating lymphoma cells may mimic acute leukemia		**Blastoid morphology of the circulating lymphoma cells may mimic acute leukemia
	**A leukemic phase with no or minimal lymph node involvement is possible, [[~~Leukemic Non~~-~~Nodal Mantle Cell Lymphoma~~]]		**A leukemic phase with no or minimal lymph node involvement is possible, [[HAEM5:Leukaemic non-nodal mantle cell lymphoma]]
	***Asymptomatic for long period		***Asymptomatic for long period
	***Splenomegaly		***Splenomegaly
Line 190:		Line 190:
	*CD10+ MCL more associated with diffuse growth pattern, blastoid/pleomorphic morphology, and BCL6 expression<ref>{{Cite journal\|last=J\|first=Xu\|last2=Lj\|first2=Medeiros\|last3=A\|first3=Saksena\|last4=M\|first4=Wang\|last5=J\|first5=Zhou\|last6=J\|first6=Li\|last7=Cc\|first7=Yin\|last8=G\|first8=Tang\|last9=L\|first9=Wang\|date=2017\|title=CD10-positive mantle cell lymphoma: clinicopathologic and prognostic study of 30 cases\|url=https://pubmed.ncbi.nlm.nih.gov/29545910/\|language=en\|doi=10.18632/oncotarget.23571\|pmc=PMC5837746\|pmid=29545910}}</ref>		*CD10+ MCL more associated with diffuse growth pattern, blastoid/pleomorphic morphology, and BCL6 expression<ref>{{Cite journal\|last=J\|first=Xu\|last2=Lj\|first2=Medeiros\|last3=A\|first3=Saksena\|last4=M\|first4=Wang\|last5=J\|first5=Zhou\|last6=J\|first6=Li\|last7=Cc\|first7=Yin\|last8=G\|first8=Tang\|last9=L\|first9=Wang\|date=2017\|title=CD10-positive mantle cell lymphoma: clinicopathologic and prognostic study of 30 cases\|url=https://pubmed.ncbi.nlm.nih.gov/29545910/\|language=en\|doi=10.18632/oncotarget.23571\|pmc=PMC5837746\|pmid=29545910}}</ref>
	*CD23: small subset of cases <ref>{{Cite journal\|last=S\|first=Kumar\|last2=Ga\|first2=Green\|last3=J\|first3=Teruya-Feldstein\|last4=M\|first4=Raffeld\|last5=Es\|first5=Jaffe\|date=1996\|title=Use of CD23 (BU38) on paraffin sections in the diagnosis of small lymphocytic lymphoma and mantle cell lymphoma\|url=https://pubmed.ncbi.nlm.nih.gov/8878025/\|language=en\|pmid=8878025}}</ref>		*CD23: small subset of cases <ref>{{Cite journal\|last=S\|first=Kumar\|last2=Ga\|first2=Green\|last3=J\|first3=Teruya-Feldstein\|last4=M\|first4=Raffeld\|last5=Es\|first5=Jaffe\|date=1996\|title=Use of CD23 (BU38) on paraffin sections in the diagnosis of small lymphocytic lymphoma and mantle cell lymphoma\|url=https://pubmed.ncbi.nlm.nih.gov/8878025/\|language=en\|pmid=8878025}}</ref>
	*CD200: May be positive in a subset of SOX11 negative mantle cell lymphomas<ref>{{Cite journal\|last=B\|first=Espinet\|last2=A\|first2=Ferrer\|last3=B\|first3=Bellosillo\|last4=L\|first4=Nonell\|last5=A\|first5=Salar\|last6=C\|first6=Fernández-Rodríguez\|last7=E\|first7=Puigdecanet\|last8=J\|first8=Gimeno\|last9=M\|first9=Garcia-Garcia\|date=2014\|title=Distinction between asymptomatic monoclonal B-cell lymphocytosis with cyclin D1 overexpression and mantle cell lymphoma: from molecular profiling to flow cytometry\|url=https://pubmed.ncbi.nlm.nih.gov/24352646/\|language=en\|doi=10.1158/1078-0432.CCR-13-1077\|pmc=PMC4488901\|pmid=24352646}}</ref> [[~~Leukemic Non~~-~~Nodal Mantle Cell Lymphoma~~]]		*CD200: May be positive in a subset of SOX11 negative mantle cell lymphomas<ref>{{Cite journal\|last=B\|first=Espinet\|last2=A\|first2=Ferrer\|last3=B\|first3=Bellosillo\|last4=L\|first4=Nonell\|last5=A\|first5=Salar\|last6=C\|first6=Fernández-Rodríguez\|last7=E\|first7=Puigdecanet\|last8=J\|first8=Gimeno\|last9=M\|first9=Garcia-Garcia\|date=2014\|title=Distinction between asymptomatic monoclonal B-cell lymphocytosis with cyclin D1 overexpression and mantle cell lymphoma: from molecular profiling to flow cytometry\|url=https://pubmed.ncbi.nlm.nih.gov/24352646/\|language=en\|doi=10.1158/1078-0432.CCR-13-1077\|pmc=PMC4488901\|pmid=24352646}}</ref> [[HAEM5:Leukaemic non-nodal mantle cell lymphoma]]
	*LEF-1: positive in 4 - 9% of mantle cell lymphomas <ref>{{Cite journal\|last=Dp\|first=O'Malley\|last2=Jp\|first2=Lee\|last3=Am\|first3=Bellizzi\|date=2017\|title=Expression of LEF1 in mantle cell lymphoma\|url=https://pubmed.ncbi.nlm.nih.gov/28038713/\|language=en\|pmid=28038713}}</ref><ref>{{Cite journal\|last=B\|first=Sander\|last2=L\|first2=Quintanilla-Martinez\|last3=G\|first3=Ott\|last4=L\|first4=Xerri\|last5=I\|first5=Kuzu\|last6=Jk\|first6=Chan\|last7=Sh\|first7=Swerdlow\|last8=E\|first8=Campo\|date=2016\|title=Mantle cell lymphoma--a spectrum from indolent to aggressive disease\|url=https://pubmed.ncbi.nlm.nih.gov/26298543/\|language=en\|pmid=26298543}}</ref>		*LEF-1: positive in 4 - 9% of mantle cell lymphomas <ref>{{Cite journal\|last=Dp\|first=O'Malley\|last2=Jp\|first2=Lee\|last3=Am\|first3=Bellizzi\|date=2017\|title=Expression of LEF1 in mantle cell lymphoma\|url=https://pubmed.ncbi.nlm.nih.gov/28038713/\|language=en\|pmid=28038713}}</ref><ref>{{Cite journal\|last=B\|first=Sander\|last2=L\|first2=Quintanilla-Martinez\|last3=G\|first3=Ott\|last4=L\|first4=Xerri\|last5=I\|first5=Kuzu\|last6=Jk\|first6=Chan\|last7=Sh\|first7=Swerdlow\|last8=E\|first8=Campo\|date=2016\|title=Mantle cell lymphoma--a spectrum from indolent to aggressive disease\|url=https://pubmed.ncbi.nlm.nih.gov/26298543/\|language=en\|pmid=26298543}}</ref>
	*Cyclin D1-negative MCL		*Cyclin D1-negative MCL
Line 600:		Line 600:
	==Links==		==Links==

	[[~~Leukemic Non~~-~~Nodal Mantle Cell Lymphoma~~]]		[[HAEM5:Leukaemic non-nodal mantle cell lymphoma]]

	[[In ~~Situ Mantle Cell Neoplasia~~]]		[[HAEM5:In situ mantle cell neoplasm]]

	Put your links here (use "Link" icon at top of page)		Put your links here (use "Link" icon at top of page)

Bailey.Glen at 18:53, 3 November 2023

2023-11-03T18:53:05Z

@@ Line 1: / Line 1: @@
 {{Under Construction}}
 ==Primary Author(s)*==
@@ Line 612: / Line 617: @@
 <nowiki>*</nowiki>The hierarchical tumour classification structure displayed on this page is reproduced from the [https://tumourclassification.iarc.who.int/welcome/ WHO Classification of Tumours] with permission from the copyright holder, ©International Agency for Research on Cancer.

Bailey.Glen: Created page with "{{Under Construction}} ==Primary Author(s)== Mahsa Khanlari, MD * Zhenya Tang, MD, PhD The University Of Texas MD Anderson Cancer Center, Department of Hematopathology, H..."

2023-11-03T18:15:33Z

Created page with "{{Under Construction}} ==Primary Author(s)*== * Mahsa Khanlari, MD * Zhenya Tang, MD, PhD The University Of Texas MD Anderson Cancer Center, Department of Hematopathology, H..."

Show changes

HAEM4:Mantle Cell Lymphoma - Revision history

Bailey.Glen at 21:36, 4 December 2023

Bailey.Glen at 18:53, 3 November 2023

Bailey.Glen: Created page with "{{Under Construction}} ==Primary Author(s)*== * Mahsa Khanlari, MD * Zhenya Tang, MD, PhD The University Of Texas MD Anderson Cancer Center, Department of Hematopathology, H..."

Bailey.Glen: Created page with "{{Under Construction}} ==Primary Author(s)== Mahsa Khanlari, MD * Zhenya Tang, MD, PhD The University Of Texas MD Anderson Cancer Center, Department of Hematopathology, H..."